---
layout: minimal-medicine
title: Alglucosidase Alfa
---

# Alglucosidase Alfa
### Generic Name
Alglucosidase Alfa

### Usage
Alglucosidase alfa is a prescription enzyme replacement therapy used to treat Pompe disease, also known as glycogen storage disease type II (GAA deficiency).  Pompe disease is a rare, inherited disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). This enzyme deficiency leads to a buildup of glycogen, a type of sugar, in various tissues throughout the body, primarily affecting muscles, including the heart and respiratory muscles.  Alglucosidase alfa provides a functional copy of the missing or deficient GAA enzyme, helping to reduce the accumulation of glycogen and alleviate symptoms.  It's used across a spectrum of Pompe disease severity, including infantile, juvenile, and late-onset forms.


### Dosage

**Important Note:**  The dosage information provided here is for general understanding and should not be interpreted as a substitute for personalized advice from a healthcare professional. Dosage adjustments may be necessary depending on the individual's response to treatment and overall health.

Dosage for both adults and children with Pompe disease (GAA deficiency) is administered intravenously (IV):

* **Typical Dosage:**  20 mg/kg every 2 weeks.  The infusion is typically given over approximately 4 hours.  The initial infusion rate is 1 mg/kg/hr IV,  potentially increasing by 2 mg/kg/hr every 30 minutes, with a maximum rate of 7 mg/kg/hr.

* **Infantile and Juvenile Onset:** The dosage is the same as for adults.

* **Dosage Adjustments:** The manufacturer's labeling doesn't currently provide specific dosage adjustments for hepatic (liver) or renal (kidney) impairment.  A healthcare provider will carefully monitor patients with these conditions and adjust treatment as needed.


### Side Effects

**Common Side Effects (occurring in more than 10% of patients):**

* Flushing
* Skin rash and urticaria (hives)
* Hypersensitivity reactions (ranging from mild to severe)
* Fever
* Development of IgG antibodies (immune response)

**Less Common but Serious Side Effects (occurring in 1-10% or less, but potentially life-threatening):**

* Anaphylaxis (severe allergic reaction)
* Chest discomfort, hypertension, decreased oxygen saturation
* Nausea, vomiting, diarrhea
* Headache, dizziness, fatigue, muscle pain
* Cough, shortness of breath
* Swelling at the infusion site

**Other Potential Side Effects (frequency not specified):**

* Bronchospasm
* Blurred vision
* Abdominal pain
* Cardiac or respiratory arrest
* Hypokalemia (low potassium)
* Nephrotic syndrome
* Necrotizing skin lesions (tissue death)
*  Immune-mediated inflammatory arthropathy


It is crucial to report any side effects to a doctor immediately.  Serious adverse reactions may require immediate medical attention.


### How it Works

Alglucosidase alfa is a recombinant human enzyme, meaning it's a laboratory-made version of the naturally occurring GAA enzyme.  In individuals with Pompe disease, the body either doesn't produce GAA or produces a non-functional version.  Alglucosidase alfa acts as a replacement for the missing or deficient enzyme.  It's administered intravenously and taken up by cells through specific receptors. Once inside the cell, it breaks down the accumulated glycogen, reducing its levels in the affected tissues and mitigating the symptoms of Pompe disease.


### Precautions

* **Hypersensitivity:** Alglucosidase alfa is contraindicated (absolutely not to be used) in patients with a known hypersensitivity to the drug or related compounds.

* **Anaphylaxis and Hypersensitivity Reactions:** There's a significant risk of life-threatening anaphylaxis and other severe hypersensitivity reactions.  Emergency medical support should be readily available during and after administration.

* **Immune-Mediated Reactions:**  Serious immune-mediated reactions, including necrotizing skin lesions and nephrotic syndrome, can occur. Careful monitoring is crucial.

* **Cardiac and Respiratory Compromise:**  Patients with pre-existing cardiac or respiratory issues are at increased risk for complications, especially during infusions. Close monitoring is vital.

* **Fluid Overload:**  Exercise caution in patients prone to fluid overload due to the infusion volume.

* **Pregnancy and Breastfeeding:**  Alglucosidase alfa is categorized as Pregnancy Category C. The effects on a developing fetus are unknown. The excretion of this medication in breast milk is unclear, hence caution is advised during breastfeeding.

* **Drug Interactions:** Currently, there is no specific information about significant drug interactions with Alglucosidase alfa. However, always inform your healthcare provider about all medications, herbal supplements, or vitamins you are taking before starting any new treatment.


### FAQs

* **Q: How long does it take to see results from Alglucosidase alfa?** A: The response to treatment varies among individuals. Some patients may see improvement in their symptoms within weeks or months, while others may require a longer period.

* **Q: How is Alglucosidase alfa administered?** A: It's administered intravenously by a healthcare professional.

* **Q: How is Alglucosidase alfa stored?** A:  Store as directed by your pharmacist.

* **Q: What should I do if I miss a dose?** A: Contact your healthcare provider immediately to discuss rescheduling the missed dose.  Do not attempt to double up on doses.

* **Q: Are there long-term effects of using Alglucosidase alfa?** A: Long-term effects and safety are being continually monitored.  Regular check-ups with your doctor are essential.

* **Q: Can Alglucosidase alfa cure Pompe disease?** A: No, it does not cure Pompe disease, but it helps manage symptoms and potentially slow disease progression.

**Disclaimer:**  This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  The information provided here may not be exhaustive, and recent updates or changes may exist. Refer to the most up-to-date prescribing information for the most accurate and comprehensive details.
